Desmopressin - Ferring Pharmaceuticals
Alternative Names: DDAVP; DDAVP Melt; Desmopressin acetate - Ferring Pharmaceuticals; FE 992026; MINIRIN; Minirin Melt; NOCDURNA; Nocdurna; Nokdurna; Noqdirna; Noqturina; Oral lyophilisate desmopressinLatest Information Update: 13 Jun 2023
Price :
$50 *
At a glance
- Originator Ferring Pharmaceuticals
- Class Antidiuretics; Antihaemorrhagics; Hormones; Peptides; Urologics; Vasoconstrictors; Vasopressins
- Mechanism of Action Hormone replacements; Vasopressin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diabetes insipidus; Enuresis; Nocturia
- Phase II Overactive bladder
Most Recent Events
- 01 Oct 2022 Antares Pharma announces intention to terminate its licence agreement with Ferring Pharmaceuticals for desmopressin sublingual in USA in October 2023
- 24 May 2022 Antares Pharma has been acquired by Halozyme Therapeutics
- 01 Oct 2020 Antares Pharma in-license desmopressin sublingual in the US for Nocturia from Ferring Pharmaceuticals